Related references
Note: Only part of the references are listed.The accumulation of deficits approach to describe frailty
Raskit Lachmann et al.
PLOS ONE (2019)
Multicenter, Randomized, Double-Blind Phase 2 Trial of FOLFIRI With Regorafenib or Placebo as Second-Line Therapy for Metastatic Colorectal Cancer
Hanna K. Sanoff et al.
CANCER (2018)
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
Kaitlyn K. H. Goey et al.
EUROPEAN JOURNAL OF CANCER (2018)
Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology
Supriya G. Mohile et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Proximal shift of colorectal cancer with increasing age in different ethnicities
Lin Yang et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Ethan Basch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
Tomohiro F. Nishijima et al.
CANCER TREATMENT REVIEWS (2016)
Long-term Toxicity of Cancer Treatment in Older Patients
Armin Shahrokni et al.
CLINICS IN GERIATRIC MEDICINE (2016)
Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010
Christina E. Bailey et al.
JAMA SURGERY (2015)
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Amylou C. Dueck et al.
JAMA ONCOLOGY (2015)
Impact of Colorectal Cancer Diagnosis and Treatment on Health-Related Quality of Life Among Older Americans: A Population-Based, Case-Control Study
Caroleen Quach et al.
CANCER (2015)
Refining the Chemotherapy Approach for Older Patients With Colon Cancer
Nadine J. McCleary et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
C. F. Jehn et al.
BRITISH JOURNAL OF CANCER (2012)
Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
S. Abdelwahab et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer
Jeffrey A. Meyerhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study
Javier Sastre et al.
ONCOLOGIST (2012)
First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
J. Sastre et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Greg Yothers et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
Matthew T. Seymour et al.
LANCET (2011)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2009)
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer:: Combined analysis of 2,691 patients in randomized controlled trials
Gunnar Folprecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741
Hanna K. Sanoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer -: An exploratory cohort of the OPTIMOX1 study
Ari Figer et al.
CANCER (2007)
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
Richard M. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Never too old?: Age should not be a barrier to enrollment in cancer clinical trials
MS Aapro et al.
ONCOLOGIST (2005)
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer:: a pooled analysis of clinical trials
G Folprecht et al.
ANNALS OF ONCOLOGY (2004)
Participation in cancer clinical trials - Race-, sex-, and age-based disparities
VH Murthy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Share Paper
